Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

B London

Showing results (181-190 of 310) with videos related to

Pageof 31
Sort By:
Pediatric Blood & Cancer|January 17, 2026
Improved Outcomes for Older Children, Adolescents, and Young Adults With Neuroblastoma in the Post-Immunotherapy Era: An Updated Report From the International Neuroblastoma Risk GroupRebecca J Deyell, Kavitha Srivatsa, Paola Angelini, et al.
Pediatric Blood & Cancer|May 15, 2013
Predictors of neoplastic disease in children with isolated pituitary stalk thickeningNathan J Robison, Sanjay P Prabhu, Pengling Sun, et al.
Cancer Research|December 29, 2011
N-Myc regulates expression of the detoxifying enzyme glutathione transferase GSTP1, a marker of poor outcome in neuroblastomaJamie I Fletcher, Samuele Gherardi, Jayne Murray, et al.
Cancer|July 7, 2005
Amifostine does not protect against the ototoxicity of high-dose cisplatin combined with etoposide and bleomycin in pediatric germ-cell tumors: a Children's Oncology Group studyNeyssa Marina, Kay W Chang, Marcio Malogolowkin, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 22, 2020
Age, Diagnostic Category, Tumor Grade, and Mitosis-Karyorrhexis Index Are Independently Prognostic in Neuroblastoma: An INRG ProjectElizabeth Sokol, Ami V Desai, Mark A Applebaum, et al.
Pediatric Blood & Cancer|August 29, 2025
Outcomes for Patients Aged 12-18 Months With Metastatic MYCN Non-Amplified Neuroblastoma and Unfavorable Biologic Features ("Mixed Biology Toddlers"): A Report From the International Neuroblastoma Risk Group (INRG) ProjectMallory R Taylor, James R Anderson, Julie R Park, et al.
Pediatric Blood & Cancer|June 17, 2009
Clinicopathological characteristics of ganglioneuroma and ganglioneuroblastoma: a report from the CCG and COGChizuko Okamatsu, Wendy B London, Arlene Naranjo, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 15, 2020
Reply to K. Beiske et alElizabeth Sokol, Ami V Desai, Mark A Applebaum, et al.
Blood Advances|October 5, 2018
Successful hematopoietic stem cell mobilization and apheresis collection using plerixafor alone in sickle cell patientsErica B Esrick, John P Manis, Heather Daley, et al.
Pediatric Blood & Cancer|November 18, 2020
A nomogram of clinical and biologic factors to predict survival in children newly diagnosed with high-risk neuroblastoma: An International Neuroblastoma Risk Group projectLucas Moreno, Dongjing Guo, Meredith S Irwin, et al.
Pageof 31

Showing results (181-190 of 310) with videos related to

Sort By:
Pageof 31
Pediatric Blood & Cancer|January 17, 2026
Improved Outcomes for Older Children, Adolescents, and Young Adults With Neuroblastoma in the Post-Immunotherapy Era: An Updated Report From the International Neuroblastoma Risk GroupRebecca J Deyell, Kavitha Srivatsa, Paola Angelini, et al.
Pediatric Blood & Cancer|May 15, 2013
Predictors of neoplastic disease in children with isolated pituitary stalk thickeningNathan J Robison, Sanjay P Prabhu, Pengling Sun, et al.
Cancer Research|December 29, 2011
N-Myc regulates expression of the detoxifying enzyme glutathione transferase GSTP1, a marker of poor outcome in neuroblastomaJamie I Fletcher, Samuele Gherardi, Jayne Murray, et al.
Cancer|July 7, 2005
Amifostine does not protect against the ototoxicity of high-dose cisplatin combined with etoposide and bleomycin in pediatric germ-cell tumors: a Children's Oncology Group studyNeyssa Marina, Kay W Chang, Marcio Malogolowkin, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 22, 2020
Age, Diagnostic Category, Tumor Grade, and Mitosis-Karyorrhexis Index Are Independently Prognostic in Neuroblastoma: An INRG ProjectElizabeth Sokol, Ami V Desai, Mark A Applebaum, et al.
Pediatric Blood & Cancer|August 29, 2025
Outcomes for Patients Aged 12-18 Months With Metastatic MYCN Non-Amplified Neuroblastoma and Unfavorable Biologic Features ("Mixed Biology Toddlers"): A Report From the International Neuroblastoma Risk Group (INRG) ProjectMallory R Taylor, James R Anderson, Julie R Park, et al.
Pediatric Blood & Cancer|June 17, 2009
Clinicopathological characteristics of ganglioneuroma and ganglioneuroblastoma: a report from the CCG and COGChizuko Okamatsu, Wendy B London, Arlene Naranjo, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 15, 2020
Reply to K. Beiske et alElizabeth Sokol, Ami V Desai, Mark A Applebaum, et al.
Blood Advances|October 5, 2018
Successful hematopoietic stem cell mobilization and apheresis collection using plerixafor alone in sickle cell patientsErica B Esrick, John P Manis, Heather Daley, et al.
Pediatric Blood & Cancer|November 18, 2020
A nomogram of clinical and biologic factors to predict survival in children newly diagnosed with high-risk neuroblastoma: An International Neuroblastoma Risk Group projectLucas Moreno, Dongjing Guo, Meredith S Irwin, et al.
Pageof 31